How further suppression of virus replication could improve current HBV treatment

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 8, 2013, Pages 755-757

  Tavis, John E ^a   Gehring, Adam J ^b   Hu, Yuan ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

curative therapy; drug development; hepatitis B virus

Indexed keywords

ADEFOVIR; CIRCULAR DNA; COVALENTLY CLOSED CIRCULAR DNA; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PEGINTERFERON ALPHA; TELBIVUDINE; TENOFOVIR; UNCLASSIFIED DRUG;

ANTIVIRAL RESISTANCE; CELLULAR IMMUNITY; DISEASE COURSE; DNA SYNTHESIS; DRUG EFFICACY; DRUG RESPONSE; GENE THERAPY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; NONHUMAN; PHARMACOLOGICAL BLOCKING; REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS PARTICLE; VIRUS REPLICATION;

DRUG RESISTANCE, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; VIRUS REPLICATION;

EID: 84887585066     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2013.814846     Document Type: Review

References (20)

1. Seeger C, Zoulim F, Mason WS. Hepadnaviruses. In: Fields Virology. Knipe DM, Howley P, Griffin De et al. (Eds). Lippincott Williams&Wilkins, Philadelphia, PA, USA, 2977-3029 (2007
2. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N. Engl. J. Med. 350(11), 1118-1129 (2004
3. Kwon H, Lok AS. Hepatitis B therapy. Nat. Rev. Gastroenterol. Hepatol. 8(5), 275-284 (2011
4. Wursthorn K, Jung M, Riva A et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 52(5), 1611-1620 (2010
5. Woo G, Tomlinson G, Nishikawa Y et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: A systematic review and Bayesian meta-Analyses. Gastroenterology 139(4), 1218-1229 (2010
6. van Bömmel F, De Man RA, Wedemeyer H et al. Long-Term efficacy of tenofovir monotherapy for hepatitis B virusmonoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 51(1), 73-80 (2010
7. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137(5), 1593-608.e1 (2009
8. Lau GK A new magic bullet for chronic hepatitis B infection: Is this the end of the story? Gastroenterology 136(5), 1830-1832; discussion 1832 (2009
9. Buti M, Brosa M, Casado MA, Rueda M, Esteban R. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J. Hepatol. 51(4), 640-646 (2009
10. Yeo W, Chan HL. Hepatitis B virus reactivation associated with anti-neoplastic therapy. J. Gastroenterol. Hepatol. 28(1), 31-37 (2013
11. Block TM, Gish R, Guo H et al Chronic hepatitis B: What should be the goal for new therapies? Antiviral Res. 98(1), 27-34 (2013
12. Coffin CS, Mulrooney-Cousins PM, Peters MG et al. Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy. J. Viral Hepat. 18(6), 415-423 (2011
13. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 284(5415), 825-829 (1999
14. Deng Q, Mancini-Bourgine M, Zhang X et al. Hepatitis B virus as a gene delivery vector activating foreign antigenic T cell response that abrogates viral expression in mouse models. Hepatology 50(5), 1380-1391 (2009
15. Kosinska AD, Johrden L, Zhang E et al. DNA prime-Adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model. J. Virol. 86(17), 9297-9310 (2012
16. Bohne F, Chmielewski M, Ebert G et al. T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. Gastroenterology 134(1), 239-247 (2008
17. Gehring AJ, Xue SA, Ho ZZ et al. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J. Hepatol. 55(1), 103-110 (2011
18. Cai D, Mills C, Yu W et al. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob. Agents Chemother. 56(8), 4277-4288 (2012
19. Tavis JE, Cheng X, Hu Y et al. The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes. PLoS Pathog. 9(1), e1003125 (2013
20. Boni C, Laccabue D, Lampertico P et al. Restored function of HBV-specific T cells after long-Term effective therapy with nucleos(t)ide analogues. Gastroenterology 143(4), 963-73.e9 (2012